XOMA vs. VNDA, EBS, VSTM, MACK, RIGL, SYRS, RGLS, LXRX, CUE, and OPK
Should you be buying XOMA stock or one of its competitors? The main competitors of XOMA include Vanda Pharmaceuticals (VNDA), Emergent BioSolutions (EBS), Verastem (VSTM), Merrimack Pharmaceuticals (MACK), Rigel Pharmaceuticals (RIGL), Syros Pharmaceuticals (SYRS), Regulus Therapeutics (RGLS), Lexicon Pharmaceuticals (LXRX), Cue Biopharma (CUE), and OPKO Health (OPK). These companies are all part of the "pharmaceutical preparations" industry.
XOMA (NASDAQ:XOMA) and Vanda Pharmaceuticals (NASDAQ:VNDA) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, valuation, analyst recommendations, earnings, media sentiment, institutional ownership, community ranking, risk and dividends.
95.9% of XOMA shares are held by institutional investors. Comparatively, 88.1% of Vanda Pharmaceuticals shares are held by institutional investors. 7.2% of XOMA shares are held by company insiders. Comparatively, 7.7% of Vanda Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Vanda Pharmaceuticals has a net margin of -2.75% compared to XOMA's net margin of -705.23%. Vanda Pharmaceuticals' return on equity of -0.90% beat XOMA's return on equity.
XOMA has a beta of 0.57, meaning that its share price is 43% less volatile than the S&P 500. Comparatively, Vanda Pharmaceuticals has a beta of 0.71, meaning that its share price is 29% less volatile than the S&P 500.
Vanda Pharmaceuticals received 104 more outperform votes than XOMA when rated by MarketBeat users. Likewise, 68.55% of users gave Vanda Pharmaceuticals an outperform vote while only 65.95% of users gave XOMA an outperform vote.
XOMA currently has a consensus target price of $57.00, suggesting a potential upside of 123.44%. Given XOMA's higher possible upside, equities analysts plainly believe XOMA is more favorable than Vanda Pharmaceuticals.
Vanda Pharmaceuticals has higher revenue and earnings than XOMA. Vanda Pharmaceuticals is trading at a lower price-to-earnings ratio than XOMA, indicating that it is currently the more affordable of the two stocks.
In the previous week, Vanda Pharmaceuticals had 1 more articles in the media than XOMA. MarketBeat recorded 3 mentions for Vanda Pharmaceuticals and 2 mentions for XOMA. Vanda Pharmaceuticals' average media sentiment score of 0.94 beat XOMA's score of 0.53 indicating that Vanda Pharmaceuticals is being referred to more favorably in the news media.
Summary
Vanda Pharmaceuticals beats XOMA on 12 of the 17 factors compared between the two stocks.
Get XOMA News Delivered to You Automatically
Sign up to receive the latest news and ratings for XOMA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding XOMA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
